Lutetium-177 PSMA RLT Toxicity Management by Neeraj Agarwal, MD, FASCO - Advanced Prostate Cancer Consensus Conference 2024 Highlights
ASCO
oncodaily.com/57183.html

#APCCC24 #ASCO #GenitourinaryOncology #OncoDaily #Oncology #CancerTreatment

Advanced Prostate Cancer Consensus Conference OncoAlert PCF Science silke gillessen #APCCC24 Advanced Prostate Cancer Consensus Conference 👉 majority of panelists favored retreating pts with mCRPC #prostatecancer with lutetium-177 RLT Rx if they had response to previous Lutetium-177 Rx lasting for more than 6 months OncoAlert PCF Science

Agnostic drug development revisited - Cancer Treatment Reviews cancertreatmentreviews.com/article/S0305-…

Non-Small Cell Lung Cancer Metastatic Without Oncogenic Alterations - PubMed pubmed.ncbi.nlm.nih.gov/38669613/?utm_…

Un experimento en moscas cuestiona una teoría de décadas sobre el origen del cáncer
En ⁦EL PAÍS⁩ elpais.com/salud-y-bienes…

Just out in ESMO open ESMO - Eur. Oncology With 44.0 months of median follow-up nivolumab/cabozantinib continues to outperform sunitinib in M1 clear cell RCC. The 3 VEGF/TKI combinations have more similarities than differences and track each other with longer follow up gbr01.safelinks.protection.outlook.com/?url=https%3A%…

O oncólogo radioterápico Antonio Gómez Caamaño, conselleiro de Sanidade Mói boa notícia para a Sanidade Galega ! toda a sorte do mundo , do bo facer non hai dubida Parabens Antonio G. C. SOG-Galicia SEOM SEOR.es redaccionmedica.com/autonomias/gal…

Desde SOG-Galicia damos la enhorabuena a un socio y compañero, Antonio G. C., por su nombramiento como Conselleiro de Sanidade Xunta de Galicia, ¡sin duda una excelente noticia para #Galicia !

Mi enhorabuena más sincera a Antonio G. C. , nuevo conselleiro de Sanidade. Gran profesional y excelente persona. Xunta de Galicia

A few details IM011 ctDNA presentation (post cystectomy MIBC) #EAU24 - it’s a subset analysis for the ctDNA -ve pts who remained -ve for a year. Analysis started post surgery not at 1 year. Those that became ctDNA +ve were excluded, pts who relapsed on CT were included (1/3)

New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47) #EAU24

#Nivolumab adyuvante mejora la supervivencia global en pacientes con cáncer de vejiga: resultados del estudio CheckMate 274
#EAU24 Matt Galsky
onconius.com/blog-1/nivolum…

Nivolumab adyuvante mejora la supervivencia global en cáncer de vejiga
Adjuvant #Nivolumab Improves Overall Survival in #BladderCancer Bristol Myers Squibb España & Portugal Sergio Vázquez

Enhorabuena a los coordinadores de las VIII Jornadas Multidisciplinares en Cáncer de Pulmón, celebradas ayer en Vigo, por el gran éxito científico y de asistencia (>100 asistentes). J.Casal, G. Huidobro y Martín Lázaro. A seguir este camino, GGCP-Galicia #LungCancer

Eagerly awaiting data from CM-274 at #EAU24 Adjuvant NIVOLUMAB showing improved OS in ITT and PD-L1 ≥1% urothelial cancers 🌟🌟🌟
#EAU24 #Oncology
Matt Galsky Tom Powles OncoAlert
Niklas Klümper Uromigos

With Matt Galsky #EAU24 adjuvant nivolumab in bladder ca: HR 0.76 in ITT & 0.56 in PD-L1 +ve. Clinically meaningful results especially in PD-L1 +ves. No data on PD-L1-ve! OS is not yet significant but this data is impressive. ~60% relapse and 24% get subsequent IO. ~10% ⬆️tox.

Adjuvant #nivolumab improves OS in patients with high risk PD-L1+ #urothelial bladder cancer post-curative intent surgery
#chekmate274

Great news!
#nivolumab #bladdercancer #adjuvant

Another MAJOR development in GU Cancers presented at #EAU24 . Nivolumab improves OS in bladder cancer ! This is major. First IO/PD1 to prolong OS in adjuvant urothelial cancer —congrats to the field, the patients, Matt Galsky and all. Major milestone!

OncoAlert joaquim bellmunt

In mild ischemic stroke, use of clopidogrel & aspirin within 24 hours after symptom onset reduces stroke recurrence. The efficacy and safety of dual antiplatelet therapy used within 72 hours have not been well studied. Full INSPIRES Research Summary: nej.md/47f7cy4